Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

Sironax' lead RIPK1 drug, SIR0365, has completed two phase 1b studies including one looking at its potential as a treatment for severe hyperinflammation associated with COVID-19 infections, while ...

Rigel Pharma surged 50.1% due to strong revenue drivers, strategic partnerships, and undervaluation, justifying a Strong Buy ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

At the event, Yuan shared the results of her research on RIPK1 — a kinase enzyme and a signalling molecule involved in cellular pathways related to cell survival and death. RIPK1 is an important ...

It’s one of two MS drugs following after tolebrutinib in Sanofi’s pipeline, alongside Denali-partnered RIPK1 inhibitor SAR443820, which is also in phase 2. Frexalimab is described by Sanofi as ...

Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San ...

Our future looks to a variety of molecules in the palate, which include of course, the BTK inhibitor, CD40-Ligand antibodies, but also our RIPK1 molecule, which is in Phase 2 for a number of the ...